Anavex Life Sciences Corp (AVXL)

[XenaLives]

If 2-73 is shown to slow the rate of cognitive decline more effectively than solanezumab or aducanumab, Anavex investors can expect terrific gains. If not, however, a complete lack of clinical-stage candidates to fall back on could result in heavy losses. With the extremely limited clinical data to base a decision on, it's hardly worth the risk.

Translation - retail don't buy yet, our "associates" are still trying desperately to accumulate.